Acute hepatitis C: Clinical and laboratory diagnosis, course of the disease, treatment

Infection

Volumn 42, Issue 4, 2014, Pages 601-610

  Sagnelli, E ^a   Santantonio, T ^b   Coppola, N ^a   Fasano, M ^b   Pisaturo, M ^a   Sagnelli, C ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Acute hepatitis C; Acute viral hepatitis; Diagnosis acute hepatitis C; Treatment acute hepatitis C

Indexed keywords

ANTIVIRUS AGENT; CORE PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN; HEPATITIS C ANTIBODY; INTERFERON;

ACUTE HEPATITIS C; ANTIVIRAL THERAPY; BLOOD TRANSFUSION; CLASSIFICATION ALGORITHM; CLINICAL FEATURE; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; EARLY DIAGNOSIS; FLOW CYTOMETRY; GOLD STANDARD; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOASSAY; INFECTION RISK; LABORATORY DIAGNOSIS; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROCONVERSION; VIRUS DIAGNOSIS; VIRUS TRANSMISSION; BLOOD; PATHOLOGY; PROCEDURES; TRANSMISSION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CLINICAL LABORATORY TECHNIQUES; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INTERFERONS; TREATMENT OUTCOME;

EID: 84906790572     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-014-0608-2     Document Type: Review

References (80)

1. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology. 2001;33:321-7. (Pubitemid 32119020)
2. Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: a chronic problem. Hepatology. 2008;47:321-31. (Pubitemid 351171069)
3. Modi AA, Feld JJ. Viral hepatitis and HIV in Africa. AIDS Rev. 2007;9:25-39. (Pubitemid 46730281)
4. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma S. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333-42.
5. Loomba R, Rivera MM, McBurney R, Park Y, Haynes-Williams V, Rehermann B, Alter HJ, Herrine SK, Liang TJ, Hoofnagle JH, Heller T. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther. 2011;33:559-65.
6. Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol. 2008;49:625-33.
7. Filippini P, Coppola N, Scolastico C, Rossi G, Onofrio M, Sagnelli E, Piccinino F. Does HIV infection favor the sexual transmission of hepatitis C? Sex Transm Dis. 2001;28:725-9. (Pubitemid 33127040)
8. Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat. 2010;17:201-7.
9. Sagnelli E, Tonziello G, Pisaturo M, Sagnelli C, Coppola N. Clinical applications of antibody avidity and immunoglobulin M testing in acute HCV infection. Antivir Ther. 2012;17:1453-8.
10. Spada E, Mele A, Mariano A, Zuccaro O, Tosti ME; SEIEVA collaborating group. Risk factors for and incidence of acute hepatitis C after the achievement of blood supply safety in Italy: results from the national surveillance system. J Med Virol. 2013;85:433-40.
11. Kim AY, Nagami EH, Birch CE, Bowen MJ, Lauer GM, McGovern BH. A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users. Hepatology. 2013;57:944-52.
12. Santantonio T, Medda E, Ferrari C, Fabris P, Cariti G, Massari M, Babudieri S, Toti M, Francavilla R, Ancarani F, Antonucci G, Scotto G, Di Marco V, Pastore G, Stroffolini T. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis. 2006;43:1154-9. (Pubitemid 44632798)
13. Indolfi G, Azzari C, Resti M. Perinatal transmission of hepatitis C virus. J Pediatr. 2013;163:1549-52.
14. Cottrell EB, Chou R, Wasson N, Rahman B, Guise JM. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158:109-13.
15. Götz HM, van Doornum G, Niesters HG, den Hollander JG, Thio HB, de Zwart O. A cluster of acute hepatitis C virus infection among men who have sex with men-results from contact tracing and public health implications. AIDS. 2005;19:969-74. (Pubitemid 40834941)
16. van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, van der Meer JT, de Vries HJ, Mulder JW, van Agtmael M, Jurriaans S, Wolthers KC, Coutinho RA. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis. 2007;196:230-8. (Pubitemid 47047462)
17. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, Fisher M, Johnson AM, Dusheiko GM; HIV and Acute HCV (HAAC) group. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS. 2007;21:983-91. (Pubitemid 46684329)
18. Lambers FA, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K, van der Meer JT, Schinkel J; MOSAIC (MSM Observational Study of Acute Infection with hepatitis C) study group. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS. 2011;25:F21-7.
19. Wandeler G, Gsponer T, Bregenzer A, Günthard HF, Clerc O, Calmy A, Stöckle M, Bernasconi E, Furrer H, Rauch A; Swiss HIV Cohort Study. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis. 2012;55:1408-16.
20. Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, Gazzard BG, Nelson M. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM in London. AIDS. 2013;27:2551-7.
21. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008;48:148-62. (Pubitemid 350191999)
22. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558-67. (Pubitemid 41196755)
23. Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill. 2008;13:pii:18880.
24. Daniels D, Grytdal S, Wasley A; Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ. 2009;58:1-27.
25. Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol. 2006;45:607-16. (Pubitemid 44316867)
26. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392-420.
27. Sagnelli E, Coppola N, Marrocco C, Coviello G, Rossi G, Battaglia M, Sagnelli C, Messina V, Tonziello A, Scolastico C, Filippini P. Diagnosis of HCV related acute hepatitis by serial determination of IgM to HCV: a preliminary observation. J Biol Regul Homeost Agents. 2003;17:207-10. (Pubitemid 37220858)
28. Sagnelli E, Coppola N, Marrocco C, Coviello G, Battaglia M, Messina V, Rossi G, Sagnelli C, Scolastico C, Filippini P. Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. J Hepatol. 2005;42:646-51.
29. Coppola N, Vatiero LM, Sagnelli E. HCV genotype 2 as a risk factor for reactivation of chronic HCV infection. Gut. 2005;54:1207. (Pubitemid 41025926)
30. Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, Sagnelli C, Starace M, Pasquale G, Coppola N. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol. 2013;11:1174-80.
31. Lu SN, Tung HD, Chen TM, Lee CM, Wang JH, Hung CH, Chen CH, Changchien CS. Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti-HCV titre rather than by seroconversion? J Viral Hepat. 2004;11:563-70. (Pubitemid 39486621)
32. Nikolaeva LI, Blokhina NP, Tsurikova NN, Voronkova NV, Miminoshvili MI, Braginsky DM, Yastrebova ON, Booynitskaya OB, Isaeva OV, Michailov MI, Archakov AI. Virus-specific antibody titres in different phases of hepatitis C virus infection. J Viral Hepat. 2002;9:429-37. (Pubitemid 35373764)
33. Araujo AC, Astrakhantseva IV, Fields HA, Kamili S. Distinguishing acute from chronic hepatitis C virus (HCV) infection based on antibody reactivities to specific HCV structural and nonstructural proteins. J Clin Microbiol. 2011;49:54-7.
34. Ward KN, Dhaliwal W, Ashworth KL, Clutterbuck EJ, Teo CG. Measurement of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibody. J Med Virol. 1994;43:367-72. (Pubitemid 24263465)
35. Kanno A, Kazuyama Y. Immunoglobulin G antibody avidity assay for serodiagnosis of hepatitis C virus infection. J Med Virol. 2002;68:229-33.
36. Coppola N, Pisapia R, Marrocco C, Martini S, Vatiero LM, Messina V, Tonziello G, Sagnelli C, Filippini P, Piccinino F, Sagnelli E. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol. 2007;40:110-5. (Pubitemid 47419428)
37. Coppola N, Pisapia R, Tonziello G, Masiello A, Martini S, Pisaturo M, Messina V, Sagnelli C, Macera M, Signoriello G, Sagnelli E. Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol. 2009;46:222-9.
38. Gaudy-Graffin C, Lesage G, Kousignian I, Laperche S, Girault A, Dubois F, Goudeau A, Barin F. Use of an anti-hepatitis C virus (HCV) IgG avidity assay to identify recent HCV infection. J Clin Microbiol. 2010;48:3281-7.
39. Quiroga JA, van Binsbergen J, Wang CY, Pardo M, Navas S, Trines C, Herrero M, Carreño V. Immunoglobulin M antibody to hepatitis C virus core antigen: correlations with viral replication, histological activity, and liver disease outcome. Hepatology. 1995;22:1635-40.
40. Chen M, Sönnerborg A, Sällberg M. Levels of hepatitis C virus (HCV) RNA in serum and their relationship to levels of immunoglobulin M and G antibodies against HCV core protein. J Clin Microbiol. 1995;33:778-80.
41. Negro F, Giostra E, Rubbia-Brandt L, Mentha G, Colucci G, Morel P, Quadri R, Perrin L, Hadengue A. IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation. J Med Virol. 1998;56:224-9. (Pubitemid 28458089)
42. Baumert TF, Wellnitz S, Aono S, Satoi J, Herion D, Tilman Gerlach J, Pape GR, Lau JY, Hoofnagle JH, Blum HE, Liang TJ. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. Hepatology. 2000;32:610-7.
43. Sheen IS, Liaw YF, Lin DY, Chu CM. Acute exacerbations in chronic hepatitis C: a clinicopathological and prognostic study. J Hepatol. 1996;24:525-31.
44. Rumi MG, De Filippi F, La Vecchia C, Donato MF, Gallus S, Del Ninno E, Colombo M. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut. 2005;54:402-6. (Pubitemid 40299098)
45. Zuccaro O, Tosti ME, Mele A, Spada E; SEIEVA Collaborating Group. Rapporti ISTISAN. 2012. No. 12/4.
46. Sagnelli E, Coppola N, Marrocco C, Onofrio M, Sagnelli C, Coviello G, Scolastico C, Filippini P. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. J Clin Virol. 2006;35:317-20. (Pubitemid 43188980)
47. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34-41.
48. Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, Shaw-Stiffel T, Weston SJ, Thiede H, Wald A, Rosen HR. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007;196:1474-82. (Pubitemid 351411983)
49. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119:1745-54.
50. Post J, Ratnarajah S, Lloyd AR. Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci. 2009;66:733-56.
51. Spada E, Amoroso P, Taliani G, Zuccaro O, Chiriacò P, Maio P, Maio G, Esposito ML, Mariano C, Rinaldi R, Bellissima P, Tosti ME, Del Porto P, Francavilla R, Mellace V, Garbuglia AR, Folgori A, Mele A; Acute Hepatitis Italian Study Group. Role of IL28B gene polymorphism and cell-mediated immunity in spontaneous resolution of acute hepatitis C. Clin Infect Dis. 2013;57:803-11.
52. Coppola N, Marrone A, Pisaturo M, Starace M, Signoriello G, Gentile I, Adinolfi LE, Sagnelli E, Zampino R. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis. 2013;(In press).
53. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, Aldegheri L, Resta S. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology. 1997;26:1393-8. (Pubitemid 27520001)
54. Coppola N, Zampino R, Bellini G, Macera M, Marrone A, Pisaturo M, Boemio A, Nobili B, Pasquale G, Maione S, Adinolfi LE, Perrone L, Sagnelli E, Miraglia Del Giudice E, Rossi F. Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014;12:334-40.
55. Omata M, Kanda T, Yu M-L, Yokosuka O, Lim S-G, Jafri W, Tateishi R, Hamid SS, Chuang W-L, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao J-H, MvCaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012;6:409-35.
56. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP; German HEP-NET Acute HCV Study Group. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43:250-6.
57. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Francavilla R, Pastore G. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol. 2005;42:329-33. (Pubitemid 40254246)
58. Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, He Q, Koziel MJ, El Naggar KM, Rasenack J, Afdhal NH. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology. 2006;130:632-8. (Pubitemid 43374512)
59. Deterding K, Grüner N, Buggisch P, Wiegand J, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Malek N, Großhennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H; Hep-Net Acute HCV-III Study Group. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis. 2013;13:497-506.
60. Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, Toti M, Perri GD, Marino N, Pizzigallo E, Angarano G; Acute Hepatitis C Study Group. Acute hepatitis C: a 24 weekcourse of Peg-interferon α-2b versus a 12 week-course of Peginterferon α-2b alone or with ribavirin. Hepatology. 2014;(Epub ahead of print). doi:10.1002/hep.26991.
61. Calleri G, Cariti G, Gaiottino F, De Rosa FG, Bargiacchi O, Audagnotto S, Quaglia S, De Blasi T, Romano P, Traverso A, Leo G, Carbone R, Del Mastro B, Tinelli M, Caramello P, Di Perri G. A short course of pegylated interferon alpha in acute HCV hepatitis. J Viral Hepat. 2007;14:116-21. (Pubitemid 46146706)
62. Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, El Gohary LA, Ramy AH, Madwar MA, Rasenack J, Afdhal NH. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology. 2006;43:923-31. (Pubitemid 43724617)
63. Broers B, Helbling B, François A, Schmid P, Chuard C, Hadengue A, Negro F; Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol. 2005;42:323-8. (Pubitemid 40254245)
64. Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, Tawil AA, Fehr JJ, Khalifa Kel S, Madwar MM, Koziel MJ. Pegylated interferon a therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology. 2004;39:1721-31. (Pubitemid 38702674)
65. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, Kullig U, Göbel U, Capka E, Wiegand J, Schiefke I, Güthoff W, Grüngreiff K, König I, Spengler U, McCarthy J, Shianna KV, Goldstein DB, McHutchison JG, Timm J, Nattermann J; German Anti-D Study Group. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterolgy. 2010;139:1586-92.
66. Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, Yeung B, Marks P, Rawlinson W, Lloyd AR, Booth D, Kaldor JM, George J, Dore GJ; ATAHC Study Group. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010;52:1216-24.
67. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim AY, McGovern BH, Schinkel J, George J, Shoukry NH, Lauer GM, Maher L, Lloyd AR, Hellard M, Dore GJ, Prins M; InC3 Study Group. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59:109-20.
68. Puoti M, Moioli MC, Travi G, Rossotti R. The burden of liver disease in human immunodeficiency virus-infected patients. Semin Liver Dis. 2012;32:103-13.
69. Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, Gazzard BG, Nelson MR. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr. 2005;40:41-6. (Pubitemid 41233203)
70. Serpaggi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, Viard JP, Piketty C, Rouveix E, Rouzioux C, Weiss L, Pol S. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS. 2006;20:233-40.
71. Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, Havlir D, Peters M. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;41:31-6. (Pubitemid 41786016)
72. Vogel M, Nattermann J, Baumgarten A, Klausen G, Bieniek B, Schewe K, Jessen H, Boesecke C, Rausch M, Lutz T, Fenske S, Schranzo D, Kümmerle T, Schuler C, Theisen A, Mayr C, Seidel T, Rockstroh JK. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther. 2006;11:1097-101. (Pubitemid 44955186)
73. Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P, Caumes E, Pialoux G, Benhamou Y, Thibault V, Katlama C. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS. 2006;20:1157-61. (Pubitemid 43786104)
74. Matthews GV, Hellard M, Haber P, Yeung B, Marks P, Baker D, McCaughan G, Sasadeusz J, White P, Rawlinson W, Lloyd A, Kaldor J, Dore GJ; Australian Trial in Acute Hepatitis C Study Group. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis. 2009;48:650-8.
75. Piroth L, Larsen C, Binquet C, Alric L, Auperin I, Chaix ML, Dominguez S, Duval X, Gervais A, Ghosn J, Delarocque-Astagneau E, Pol S; Steering Committee of the HEPAIG Study. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study. Hepatology. 2010;52:1915-21.
76. Grebely J, Hellard M, Applegate T, Petoumenos K, Yeung B, Feld JJ, Rawlinson W, Lloyd AR, George J, Kaldor JM, Dore GJ, Matthews GV; ATAHC Study Group. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS. 2012;26:1653-61.
77. European AIDS Clinical Society (EACS). Guidelines 2013 (v 7.0, October 2013). http://www.eacsociety.org.
78. Fierer DS, Dieterich DT, Mullen MP, Branch AD, Uriel AJ, Carriero DC, van Seggelen WO, Hijdra RM, Cassagnol DG; New York Acute Hepatitis C Surveillance Network. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis. 2014;58:873-9.
79. Fabrizi F, Dixit V, Messa P, Martin P. Interferon therapy of acute hepatitis C in dialysis patients: meta-analysis. J Viral Hepat. 2012;19:784-91.
80. De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Calleri G, Lesioba O, Belloro S, Raiteri R, Di Perri G. Twelve-week treatment of acute hepatitisCvirus with pegylated interferon- alpha -2b in injection drug users. Clin Infect Dis. 2007;45:583-8. (Pubitemid 47328638)